Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (... (

HOME >> BIOLOGY >> TECHNOLOGY

Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)

Date:2/18/2009

- Conference Call Scheduled for February 25, 2009, 5:00 p.m. U.S. ET -

EXTON, Pa., Feb. 18 /PRNewswire-FirstCall/ -- Adolor Corporation (Nasdaq: ADLR) today announced that it will hold a conference call at 5:00 p.m. ET on Wednesday, February 25, 2009 to discuss fourth quarter and year end financials and an update on the launch of ENTEREG(R) (alvimopan).

To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers, or (706) 902-1952 for international callers, and enter Conference ID # 85748128. Investors also can listen to the call live by logging on to the Company's website at www.adolor.com and clicking on "Investor Insights," then "Calendar of Events."

A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter Conference ID # 85748128 or listen via Adolor's website. The replay will be available for one week.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor's first approved product in the United States is ENTEREG(R) (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the Entereg Access Support and Education (E.A.S.E.) Program. In collaboration with GlaxoSmithKline, the company launched ENTEREG in mid-2008. For more information, visit '/>"/>

SOURCE Adolor Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...

(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...

(Date:6/18/2013)... In support of Swiss contributions to ... of Switzerland in New York is pleased to welcome ... PlanetSolar , to Manhattan. PlanetSolar is in New ... tour with scientists on board from the University of ... exclusively on energy from the sun and eliminates the ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...

... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...

... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...

Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2 IsoTis Adjourns Special Meeting to October 23, 2007 3 IsoTis Adjourns Special Meeting to October 23, 2007 4 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6

IsoTis Adjourns Special Meeting to October 23, 2007 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy

(Date:6/18/2013)... , June 19, 2013 Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...

(Date:6/18/2013)... at the University of Calgary,s Faculty of Medicine have ... body from harmful bacteria. Platelets, a component of blood ... for specific bacteria, and upon detection, seal it off ... were published in Nature Immunology this week, ... immunity. , "The science community has known that platelets ...

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2 Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3 Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2

[0] Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show [0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research

... the growing demand from the public and the scientific ... Press has revised its copyright policy to allow authors ... three journals. The policy, which became effective May 1, ... Journal of Cell Biology, The Journal of Experimental Medicine ...

... the human genome has been sequenced, research into mechanism of ... most human genes have not been isolated. This is true ... protein kinases, which mediate the majority of signaling events in ... It has been estimated by systematic gene sequencing efforts that ...

... which he calls a "smarthroscope", may be able to ... could be useful in developing countries. It aims ... the tissue surrounding an area affected by illnesses such ... and bone damage. The instrument would also help ...

Cached Biology News:Rockefeller University Press allows authors to retain copyright to their published work 2 QUT researchers develop smart instrument for tissue damage assessment 2

Rockefeller University Press allows authors to retain copyright to their published work Researchers report the cloning of a key group of human genes, the protein kinases QUT researchers develop smart instrument for tissue damage assessment

... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...

... The reliable and compact GC-8A is ... applications. Economical and simple to use, the ... or flow control, on column injection port(s), ... ramp program models are available. The GC-8A ...

... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...

... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...

Biology Products:

LTQ XL with ETD from Thermo Scientific GC-8 Gas Chromatograph from Shimadzu 6820 GC from Agilent Technologies 7890A GC from Agilent Technologies